Open AccessScientific Opinion on the substantiation of a health claim related to Opti EFAX ™ and maintenance of normal blood HDL‐cholesterol concentrations pursuant to Article 13(5) of Regulation (EC) No 1924/2006
Publication year - 2012
Publication title -
efsa journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.076
H-Index - 97
ISSN - 1831-4732
DOI - 10.2903/j.efsa.2012.2803
Subject(s) - health claims on food labels , authorization , health maintenance , population , blood cholesterol , medicine , cholesterol , normal population , environmental health , endocrinology , food science , biology , law , health care , political science , computer security , computer science
Following an application from Nutrilinks Sarl, submitted for authorisation of a health claim pursuant to Article 13(5) of Regulation (EC) No 1924/2006 via the Competent Authority of Belgium, the Panel on Dietetic Products, Nutrition and Allergies (NDA) was asked to deliver an opinion on the scientific substantiation of a health claim related to Opti EFAX ™ and maintenance of normal blood HDL‐cholesterol concentrations. The food that is the subject of the health claim, Opti EFAX ™, which is standardised pure krill oil, is sufficiently characterised in relation to the claimed effect. The claimed effect, maintenance of normal blood HDL‐cholesterol concentrations, is a beneficial physiological effect. The target population proposed by the applicant is the general population. No human studies have been provided from which conclusions could be drawn for the scientific substantiation of the claim. A cause and effect relationship has not been established between the consumption of Opti EFAX ™ and maintenance of normal blood HDL‐cholesterol concentrations.